On July 23, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of rituximab-pvvr (Ruxience, Pfizer), a biosimilar to rituximab
Read More >On June 10, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of polatuzumab vedotin-piiq (POLIVY, Genentech, Inc.) for adult
Read More >On May 28, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of lenalidomide (REVLIMID, Celgene Corporation) in combination with
Read More >On May 24, 2019, the U.S. Food and Drug Administration (FDA) announced it has approved the use of ruxolitinib (JAKAFI, Incyte Corporation) for steroid-refractory acute
Read More >New York (May 15, 2019) – The U.S. Food and Drug Administration (FDA) announced it has approved the use of venetoclax (VENCLEXTA, AbbVie Inc. and
Read More >
ECHELON-2 is the first study in patients with PTCL to show an improvement in overall survival over a standard therapy such as CHOP
Read More >New York, NY –The U.S. Food and Drug Administration (FDA) announced it has approved the use of ibrutinib (IMBRUVICA) in combination with obinutuzumab (GAZYVA) for
Read More >New York, NY – The U.S. Food and Drug Administration (FDA) announced it has expanded the approved use of brentuximab vedotin (ADCETRIS) injection in combination
Read More >
The Lymphoma Research Foundation extends its heartfelt condolences to the family, loved ones and colleagues of Paul Allen. Mr. Allen contributed greatly to science, philanthropy
Read More >New York, NY – The U.S. Food and Drug Administration (FDA) announced it has approved the use of duvelisib (COPIKTRA) for the treatment of adult
Read More >
